全球首个复方老花眼滴眼液获FDA批准上市，兆科眼科-B(6622.HK)抢占眼科创新赛道先机

Core Insights - The approval of BRIMOCHOL™ PF marks a significant breakthrough in the treatment of presbyopia, introducing the world's first combination eye drop for this condition [2][4][11] - The drug's approval by the FDA highlights its efficacy and safety, addressing a substantial unmet clinical need in the presbyopia treatment market [4][5][11] Drug Approval and Clinical Data - BRIMOCHOL™ PF has been validated through two key Phase III clinical trials, demonstrating superior efficacy compared to its individual active components [4][5] - The first Phase III trial (BRIO-I) confirmed the drug's effectiveness, while the second trial (BRIO-II) showed significant improvements in uncorrected near visual acuity without compromising distance vision [4][5] - The drug has shown good tolerability with no serious treatment-related adverse events reported during over 72,000 treatment days [4][5] Market Potential and Strategic Positioning - Approximately 1.2 billion people globally are affected by presbyopia, with a significant portion of the population over 50 years old impacted [5] - The approval of BRIMOCHOL™ PF fills a market gap for combination therapies in presbyopia, positioning the company favorably against competitors [5][11] - The company is actively pursuing global business development (BD) partnerships, having licensed the drug to eight countries in the Asia-Pacific region and six in the Middle East [2][6][8] Business Development Strategy - The company's BD strategy focuses on leveraging partnerships to expedite market entry in key regions, contrasting with the self-reliant approach of some competitors [6][8] - The FDA's approval is expected to facilitate faster regulatory processes in other countries, potentially simplifying or waiving clinical trial requirements based on FDA data [8][9] - This proactive approach is anticipated to significantly shorten the commercialization timeline compared to the typical 3-5 year approval cycle in the region [9] Financial Outlook and Growth Potential - The approval of BRIMOCHOL™ PF is expected to be a core revenue driver for the company in the coming years, alongside other innovative products in its pipeline [9][11] - The company's stock has shown a recovery, with a more than 150% increase since 2025, reflecting positive market expectations for its growth [11] - The ongoing development of other products, such as cyclosporine eye gel and low-concentration atropine, further supports the company's international expansion and diversification strategy [9][11]